RESUMO
The rational design, syntheses and evaluation of potent sulfonamidopyrrolidin-2-one-based factor Xa inhibitors incorporating aminoindane and phenylpyrrolidine P4 motifs are described. These series delivered highly potent anticoagulant compounds with excellent oral pharmacokinetic profiles; however, significant time dependant P450 inhibition was an issue for the aminoindane series, but this was not observed with the phenylpyrrolidine motif, which produced candidate quality molecules with potential for once-daily oral dosing in humans.
Assuntos
Inibidores do Fator Xa , Pirrolidinas/química , Pirrolidinas/farmacologia , Inibidores de Serina Proteinase/química , Inibidores de Serina Proteinase/farmacologia , Desenho de Fármacos , Modelos Moleculares , Relação Estrutura-AtividadeRESUMO
The discovery and evaluation of potent and long-acting oral sulfonamidopyrrolidin-2-one factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs are described. Unexpected selectivity issues versus tissue plasminogen activator in the former series were addressed in the later, delivering a robust candidate for progression towards clinical studies.
Assuntos
Benzazepinas/síntese química , Inibidores do Fator Xa , Inibidores de Serina Proteinase/química , Tetra-Hidroisoquinolinas/química , Administração Oral , Animais , Benzazepinas/administração & dosagem , Benzazepinas/farmacologia , Cristalografia por Raios X , Avaliação Pré-Clínica de Medicamentos , Estrutura Molecular , Ratos , Inibidores de Serina Proteinase/administração & dosagem , Tetra-Hidroisoquinolinas/administração & dosagem , Tetra-Hidroisoquinolinas/farmacologiaRESUMO
Structure and property based drug design was exploited in the synthesis of sulfonamidopyrrolidin-2-one-based factor Xa inhibitors, incorporating neutral and basic monoaryl P4 groups, ultimately producing potent inhibitors with effective levels of anticoagulant activity and extended oral pharmacokinetic profiles. However, time dependant inhibition of Cytochrome P450 3A4 was a particular issue with this series.
Assuntos
Anticoagulantes/química , Fator X/antagonistas & inibidores , Pirrolidinonas/química , Anticoagulantes/síntese química , Anticoagulantes/farmacologia , Sítios de Ligação , Simulação por Computador , Cristalografia por Raios X , Desenho de Fármacos , Fator X/metabolismo , Pirrolidinonas/síntese química , Pirrolidinonas/farmacologia , Relação Estrutura-AtividadeRESUMO
The introduction of a functionalised amido substituent into a series of 1-(biphenylmethylacetamido)-pyrimidones has given a series of inhibitors of recombinant lipoprotein-associated phospholipase A(2) with sub-nanomolar potency and very encouraging developability properties. Diethylaminoethyl derivative 32, SB-435495, was selected for progression to man.
Assuntos
Compostos de Bifenilo/farmacologia , Inibidores Enzimáticos/farmacologia , Lipoproteínas/metabolismo , Fosfolipases A/antagonistas & inibidores , Pirimidinonas/farmacologia , Administração Oral , Animais , Compostos de Bifenilo/administração & dosagem , Compostos de Bifenilo/química , Compostos de Bifenilo/metabolismo , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/química , Inibidores Enzimáticos/metabolismo , Humanos , Fosfolipases A/metabolismo , Pirimidinonas/administração & dosagem , Pirimidinonas/química , Pirimidinonas/metabolismo , Coelhos , Relação Estrutura-AtividadeRESUMO
A series of 1-(biphenylmethylamidoalkyl)-pyrimidones has been designed as nanomolar inhibitors of recombinant lipoprotein-associated phospholipase A(2) with high potency in whole human plasma. 5-(Pyrazolylmethyl) derivative 16 and 5-(methoxypyrimidinylmethyl) derivative 27 demonstrated excellent pharmacodynamic profiles which correlated well with their pharmacokinetic effects.